CLCS
Cell Source, Inc.Company Information
- Company Name
- Cell Source, Inc.
- CIK
- CIK0001569340
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CLCS: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CLCS
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- —
- Institutional shares owned
- —
- Shares outstanding
- —
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-05-14
- Price on filing date
- —
- 1-month reaction
- 0.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | ||||||
Assets Current | ||||||||||||||||||
| Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | ||||||
| Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | 1 | 1 | 2 | ||||||
| Interest Payable Current | - | - | - | 0 | - | - | - | - | - | 1 | 1 | 1 | ||||||
| Deferred Compensation Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Notes Payable Related Parties Classified Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Convertible Debt Current | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | ||||||
| Derivative Liabilities Current | - | - | - | - | 0 | 0 | - | - | - | - | - | - | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Dividends Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 20 | 19 | 19 | 18 | 17 | 16 | 16 | 15 | 14 | 13 | 12 | 11 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | -20 | -19 | -19 | -17 | -17 | -16 | -16 | -15 | -14 | -13 | -12 | -11 | ||||||
| Additional Paid In Capital | 27 | 28 | 27 | 27 | 26 | 26 | 25 | 24 | 24 | 24 | 23 | 23 | ||||||
| Retained Earnings Accumulated Deficit | -48 | -46 | -46 | -44 | -43 | -42 | -41 | -39 | -38 | -36 | -35 | -34 | ||||||
| Liabilities And Stockholders Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 45 | 45 | 43 | 42 | 41 | 40 | 38 | 38 | 37 | 36 | 0 | 35 | ||||||
| Shares Outstanding | 45 | 45 | 43 | 42 | 41 | 40 | 38 | 38 | 37 | 36 | 35 | 35 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCell Source, Inc. (CLCS) — SEC Financial Statements & Analysis
Cell Source, Inc. (CLCS) is a pharmaceutical preparations company, incorporated in NV. Cell Source, Inc. trades on OTC as: CLCS. Cell Source, Inc. (CLCS)'s most recent SEC filing is a Form 10-Q for the period ended 2025-03-31, filed with the SEC on 2026-05-14. Based on that filing, Cell Source, Inc. carries a market cap of $14.40M, a P/E ratio of -3.28x, a P/B ratio of -0.72x, an enterprise value of $14.72M, and an EV/EBITDA multiple of -3.98x. On profitability, it posts a Return on Equity (ROE) of 23.81%. Per share, it reports EPS of $-0.10, diluted EPS of $-0.10, free cash flow per share of $-0.07, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -28.73% year-over-year and EPS growth of -35.90% year-over-year. On the balance sheet, it maintains an interest coverage ratio of -71.68x, free cash flow of $-3.11M (TTM), and net debt of $313.75K. Figures sourced from SEC EDGAR.
- Market Cap
- $14.40M
- P/E TTM
- -3.28x
- EPS TTM
- $-0.10
- P/B TTM
- -0.72x
- ROE TTM
- 23.81%
- Free Cash Flow TTM
- $-3.11M
Data as of 2025-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cell Source, Inc. in?
Cell Source, Inc. (CLCS) operates in the Pharmaceutical Preparations industry.
What exchange does CLCS trade on?
Cell Source, Inc. (CLCS) trades on the OTC.
Where is Cell Source, Inc. incorporated?
Cell Source, Inc. is incorporated in NV.
When was Cell Source, Inc. (CLCS)'s most recent SEC filing?
Cell Source, Inc. (CLCS)'s most recent SEC filing is a Form 10-Q for the period ended 2025-03-31, filed with the SEC on 2026-05-14.
What is CLCS's market cap?
Cell Source, Inc. (CLCS) has a market capitalization of $14.40M as of 2025-03-31.
What is CLCS's EPS (earnings per share)?
Cell Source, Inc. (CLCS)'s trailing twelve month EPS is $-0.10 as of 2025-03-31.
What is CLCS's ROE (return on equity)?
Cell Source, Inc. (CLCS)'s trailing twelve month Return on Equity (ROE) is 23.81% as of 2025-03-31.
What is CLCS's EV/EBITDA?
Cell Source, Inc. (CLCS)'s trailing twelve month EV/EBITDA is -3.98x as of 2025-03-31.